Background There is large and significant regional variation in out-of-hospital cardiac arrest (OHCA), and despite advances in treatment, survival remains low. The American Heart Association has called for the creation of integrated cardiac resuscitation systems of care capable of measuring and improving evidence-based care from bystanders through to hospital discharge. Methods The HeartRescue Project was initiated in 2010 by the Medtronic Foundation in collaboration with 5 academic medical centers and American Medical Response. The HeartRescue Project aims to develop regional cardiac resuscitation systems of care that will implement guideline-based best practice bystander, prehospital, and hospital care with standardized data reporting linked to outcomes. The primary goal is to improve collective OHCA survival by 50% over 5 years. Results The total population in the 5 participating states is 41.1 million. At baseline, the HeartRescue Project covers approximately 26.1 million people (63.6%) and has engaged 767 emergency medical services agencies and 269 hospitals. Data will be collected for quality improvement, to inform provider feedback, and serve to define effective strategies to improve cardiac arrest care. Conclusion The HeartRescue Project is the largest public health initiative of its kind focused entirely on cardiac arrest outcomes. The project is designed to significantly improve OHCA survival by implementing and measuring model systems of care for cardiac resuscitation.
|Original language||English (US)|
|Journal||American Heart Journal|
|State||Published - Oct 2013|
Bibliographical noteFunding Information:
S.V.D., none. B.S.A. reports research grants from the NIH, Doris Duke Foundation, Medtronic Foundation, and Philips Healthcare; honoraria from Medivance; consultancy fees from Velomedix and Heartsine. B.J.B. reports research grants from the Medtronic Foundation. G.J.N. serves as a Medic One and American Heart Association Western State Board member; has served as an unpaid research collaborator with Gambro Renal, Inc, and Cytosorbents, Inc; has received travel reimbursement from the American Heart Association; institutional grants have been received from the NIH, National Health and Medical Research Council of Australia, GE health care, and the Medtronic foundation. J.G.J. has received research grants from Medtronic. J.M. is employed by Medtronic. E.M.R. is employed by the American Medical Response. D.Y. reports research grants from the NIH and Medtronic Foundation. C.B.G. and M.R.S. report research grants from the Medtronic Foundation. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.